Amir Sharon

Amir Sharon

Auto-generated profile, based on publicly available information

Amir Sharon

The Heart and Vascular Center, Chaim Sheba Medical Center , Tel HaShomer , Israel

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2023 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
ULUri Landes
Uri Landes
AHAviram Hochstadt
Aviram Hochstadt
LMLisa Manevich
Lisa Manevich
JWJohn G Webb
John G Webb
JSJanarthanan Sathananthan
Janarthanan Sathananthan
HDHaim Danenberg
Haim Danenberg
Aims: Paravalvular regurgitation (PVR) after transcatheter aortic valve implantation (TAVI) is associated with increased morbidity and mortality. The effect of transcatheter interventions to treat PVR after the index TAVI was investigated.Methods and results: A registry of consecutive patients who underwent transcatheter intervention for ≥ moderate PVR after the index TAVI at 22 centers. The principal outcomes were residual aortic regurgitation (AR) and mortality at 1 year after PVR treatment. A total of 201 patients were identified: 87 (43%) underwent redo-TAVI, 79 (39%) plug closure, and 35 (18%) balloon valvuloplasty. Median TAVI-to-re-intervention time was 207 (35; 765) days. The failed valve was self-expanding in 129 (63.9%) patients. The most frequent devices utilized were a Sapien 3 valve for redo-TAVI (55, 64%), an AVP II as plug (33, 42%), and a True balloon for valvuloplasty (20, 56%). At 30 days, AR ≥ moderate persisted in 33 (17.4%) patients: 8 (9.9%) after redo-TAVI, 18 (25.9%) after plug, and 7 (21.9%) after valvuloplasty (P = 0.036). Overall mortality was 10 (5.0%) at 30 days and 29 (14.4%) at 1 year: 0, 8 (10.1%), and 2 (5.7%) at 30 days (P = 0.010) and 11 (12.6%), 14 (17.7%), and 4 (11.4%) at 1 year (P = 0.418), after redo-TAVI, plug, and valvuloplasty, respectively. Regardless of treatment strategy, patients in whom AR was reduced to ≤ mild had lower mortality at 1 year compared with those with AR persisting ≥ moderate [11 (8.0%) vs. 6 (21.4%); P = 0.007].Conclusion: This study describes the efficacy of transcatheter treatments for PVR after TAVI. Patients in whom PVR was successfully reduced had better prognosis. The selection of patients and the optimal PVR treatment modality require further investigation.

1 July 2022 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
BFBoris Fishman
Boris Fishman
ASAmir Sharon
Amir Sharon
EIEdward Itelman
Edward Itelman
ATAvishai M Tsur
Avishai M Tsur
PFPaul Fefer
Paul Fefer
EMElad Maor
Elad Maor

3 October 2022 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
ASAmir Sharon
Amir Sharon
EMEias Massalha
Eias Massalha
BFBoris Fishman
Boris Fishman
PFPaul Fefer
Paul Fefer
IBIsrael M. Barbash
Israel M. Barbash
EMElad Maor
Elad Maor

14 October 2022 in European Heart Journal: Acute Cardiovascular Care
Verified
Journal Article
Closed access
PDF file
ASAmir Sharon
Amir Sharon
BFBoris Fishman
Boris Fishman
EMEias Massalha
Eias Massalha
EIEdward Itelman
Edward Itelman
MMMeir Mouallem
Meir Mouallem
EMElad Maor
Elad Maor
Aims: To evaluate the effect of an intercurrent non-coronary illness on the management and outcome of patients with non-ST-segment elevation myocardial infarction (NSTEMI). Methods and results: Consecutive hospitalized patients with a primary diagnosis of NSTEMI between August 2008 and December 2019 at Sheba Medical Center. All patients’ records were reviewed for the presence of a non-coronary precipitating event (NCPE): a major intercurrent acute non-coronary illness or condition, either cardiac or non-cardiac. The primary outcome was all-cause mortality. Cox regression with interaction analysis was applied. Final study population comprised 6491 patients, of whom 2621 (40%) had NCPEs. Patients with NCPEs were older (77 vs. 69 years) and more likely to have comorbidities. The most prevalent event was infection (35%, n = 922). During a median follow-up of 30 months, 2529 patients died. Patients with NCPEs were 43% more likely to die during follow-up in a multivariable model (95% CI: 1.31–1.55). Invasive strategy was associated with a 55% lower mortality among patients without NCPE and only 44% among patients with NCPE (P for interaction < 0.001). Dual antiplatelet therapy (DAPT) was associated with a 20% lower mortality in patients without NCEP and a non-significant mortality difference among patients with NCPE (P for interaction = 0.014). Sub-analysis by the specific NCPE showed the highest mortality risk among patients with infectious precipitant. The lower mortality associated with invasive strategy was not observed in this subgroup. Conclusion: Among NSTEMI patients, the presence of an NCPE is associated with poor survival and modifies the effect of management strategies.

1 October 2022 in European Heart Journal
Verified
Journal Article
Open access
PDF file
MSMichael Shechter
Michael Shechter
HCH Cohen
H Cohen
ASA Sharon
A Sharon
NKN Koren-Morag
N Koren-Morag
Ehud GrossmanEhud Grossman
Ehud Grossman
EMElad Maor
Elad Maor
In Israel, the rate of drinking water from desalinated sea water has increased dramatically to 60% in the last two decades. However, desalinated water lacks magnesium. Hypomagnesemia is associated with adverse cardiovascular outcome. To investigate the association of admission serum magnesium levels (sMg) with long-term survival of non-ST-elevation myocardial infarction (NSTEMI) patients in the light of increased use of desalinated sea water. A single-center, retrospective cohort of consecutive petients who were hospitalized with NSTEMI as their primary clinical diagnosis between August 1, 2008 to March 31, 2021. Multivariate Cox regression model was applied for mortality risk. Study population included 5,675 NSTEMI patients with a mean age of 71±13 years (range 25 to 110), of whom 3,820 (67%) were males. Mean and median sMg levels were 2.0±0.2 (0.5–6.8), 2.0 mg/dL, respectively. During mean follow-up of 4.1±2.9 years (0–14), 2,238 (39%) patients died. Mortality rate was u-shaped when associated with sMg levels (Figure 1) and the study cohort was divided into quintiles according to the sMg levels (≤1.80; 1.81–1.94; 1.95–2.00; 2.01–2.20; ≥2.21). Patients in the highest compared to the lowest sMg quintiles had significantly higher incidence of renal dysfunction with lower eGRF EPI (62±32 vs 76±26 ml/min/1.73 m2, p<0.001) and lower fasting serum glucose (102±37 vs 115±46 mg/dL, p<0.001). All-cause mortality rate was the highest in the lowest and highest sMg quintiles (48%, 33%, 32%, 33% 54%, respectively, p<0.00). Compared to the 2nd sMg quintile (1.81–1.94 mg/dL), with the lowest mortality risk, the lower sMg quintile was associated with a significant and indpendent 24% increased risk of death in a multivariate model (95% CI 1.07–1.44, p<0.001), while the highest quintile was associated with 48% increased risk (95% CI 1.25–1.74, p<0.01) (Figure 2). Admission low sMg is associated with long-term all-cause mortality in NSTEMI patients. Additionally, long-term mortality is also high in NSTEMI patients with renal dysfunction-induced high sMg levels. Type of funding sources: None. Figure 1 Figure 2